Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial to see if other drugs affect the way bortezomib works in people with non Hodgkin lymphoma and myeloma
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial is looking at whether other drugs affect the way the body breaks down bortezomib (Velcade) in people with non Hodgkin lymphoma or myeloma that has continued to grow.
More about this trial
Bortezomib is a type of biological therapy called a proteasome inhibitor. Doctors use it to treat myeloma that has come back after treatment. Clinical trials are currently looking at using bortezomib for people with non Hodgkin lymphoma.
This trial is looking at the effect of two drugs on bortezomib. The first is rifampicin. Rifampicin is not used to treat cancer. It is an antibiotic used to treat or prevent infections. The second is a steroid called dexamethasone. These two drugs activate an
The CYP3A4 enzyme breaks down bortezomib. Doctors think that rifampicin and dexamethasone will lower the amount of bortezomib because they increase the amount of the CYP3A4 enzyme. This may affect the way that bortezomib works. But researchers are not sure yet.
The results of this study may help doctors to improve treatment for people with myeloma and non Hodgkin lymphoma in the future.
Summary of results
Despite attempting to contact the trial team, we have been unable to check the results of this trial.
How to join a clinical trial
Prof Simon Rule
Johnson and Johnson Pharmaceutical R+D